Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Cryopreservation Changes the Immune Effector Cell Composition of Peripheral Blood Stem Cell Grafts: An Analysis from the DKMS and NMDP Graft Composition Study

Blood (2023) 142 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2023-179140

Published: 2023

Journal Articles

MAIT Cell Frequencies within PBSC Grafts Are Associated with Donor CMV Serostatus and Age: An Initial Analysis from the DKMS and NMDP Graft Composition Study

Blood (2023) 142 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2023-185153

Published: 2023

Journal Articles

Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells

Amy Kimball, MD, PhD, Mehmet Burcu, BS, Kieran L O’Loughlin, MS, Laurie A. Ford, Hans Minderman, Maria Baer

Blood (2008) 112 (11): 5021.

https://doi.org/10.1182/blood.V112.11.5021.5021

Published: 2008

Journal Articles

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Kieran L. O’Loughlin, BS, Hans Minderman, PhD, Laurie A. Ford, BS, Maria R. Baer, MD

Blood (2007) 110 (11): 2380.

https://doi.org/10.1182/blood.V110.11.2380.2380

Published: 2007

Journal Articles

Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Ben L. Sanford, MS, Sandra M. Bothun, BS, Krzysztof Mrozek, PhD, Kieran L. O’Loughlin, BS, Jonathan E. Kolitz, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Bayard L. Powell, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 296.

https://doi.org/10.1182/blood.V110.11.296.296

Published: 2007

Journal Articles

Randomized Trial of GM-CSF and G-CSF Following High-Dose Cytarabine and Mitoxantrone Chemotherapy for Relapsed and Refractory Acute Leukemia.

Maria R. Baer, MD, Laurie A. Ford, BS, Brian N. Bundy, PhD, Sheila M. Tighe, BS, Kieran L. O’Loughlin, MS, James L. Slack, MD, Meir Wetzler, MD, Paul K. Wallace, PhD

Blood (2006) 108 (11): 4574.

https://doi.org/10.1182/blood.V108.11.4574.4574

Published: 2006

Journal Articles

The FLT3 Inhibitor PKC412 Interacts Synergistically with Both Daunorubicin and Cytarabine in Acute Myeloid Leukemia (AML) Cells by Heterogeneous Mechanisms.

Maria R. Baer, MD, Kareemah L. Sabur, Kieran L. O’Loughlin, BS, Petr Starostik, MD, Hans Minderman, PhD

Blood (2006) 108 (11): 1378.

https://doi.org/10.1182/blood.V108.11.1378.1378

Published: 2006

Journal Articles

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Michael A. Caligiuri, MD, Ben L. Sanford, MS, Kieran L. O’Loughlin, MS, Krysztof Mrozek, PhD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 424.

https://doi.org/10.1182/blood.V108.11.424.424

Published: 2006

Journal Articles

The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.

Attaphol Pawarode, MD, Kieran L. O’Loughlin, MS, Nicholas W. Cuviello, William R. Greco, PhD, Laurie A. Ford, BS, Hans Minderman, PhD, Maria R. Baer, MD

Blood (2005) 106 (11): 1512.

https://doi.org/10.1182/blood.V106.11.1512.1512

Published: 2005

Journal Articles

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Misbah Qadir, MD, Kieran L. O’Loughlin, MS, Nicole A. Williamson, BA, Hans Minderman, PhD, Maria R. Baer, MD

Blood (2004) 104 (11): 1180.

https://doi.org/10.1182/blood.V104.11.1180.1180

Published: 2004

Journal Articles

Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance.

Stacy M. Fricke, BS, Hans Minderman, PhD, Kieran L. O’Loughlin, MS, Jinrong Cheng, MS, Elizabeth A. Repasky, PhD, Maria R. Baer, MD

Blood (2004) 104 (11): 4385.

https://doi.org/10.1182/blood.V104.11.4385.4385

Published: 2004

Journal Articles

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

Maria R. Baer, Stephen L. George, Richard K. Dodge, Kieran L. O'Loughlin, Hans Minderman, Michael A. Caligiuri, John Anastasi, Bayard L. Powell, Jonathan E. Kolitz, Charles A. Schiffer, Clara D. Bloomfield, Richard A. Larson

Blood (2002) 100 (4): 1224–1232.

https://doi.org/10.1182/blood.V100.4.1224.h81602001224_1224_1232

Published: 2002

Journal Articles

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia

Udomsak Bunworasate, Hilal Arnouk, Hans Minderman, Kieran L. O'Loughlin, Sheila N. J. Sait, Maurice Barcos, Carleton C. Stewart, Maria R. Baer

Blood (2001) 98 (12): 3492–3494.

https://doi.org/10.1182/blood.V98.12.3492

Published: 2001

NARROW

Cryopreservation Changes the Immune Effector Cell Composition of Peripheral Blood Stem Cell Grafts: An Analysis from the DKMS and NMDP Graft Composition Study

MAIT Cell Frequencies within PBSC Grafts Are Associated with Donor CMV Serostatus and Age: An Initial Analysis from the DKMS and NMDP Graft Composition Study

Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells

Amonafide L-Malate Bypasses Multidrug Resistance Proteins in Secondary Acute Myeloid Leukemia.

Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720).

Randomized Trial of GM-CSF and G-CSF Following High-Dose Cytarabine and Mitoxantrone Chemotherapy for Relapsed and Refractory Acute Leukemia.

The FLT3 Inhibitor PKC412 Interacts Synergistically with Both Daunorubicin and Cytarabine in Acute Myeloid Leukemia (AML) Cells by Heterogeneous Mechanisms.

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance.

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only